Skip to content

Effect and Mechanism of Neoadjuvant Therapy on Residual Neuromuscular Relaxation following Deep Neuromuscular Blockade

Effect and Mechanism of Neoadjuvant Therapy on Residual Neuromuscular Relaxation following Deep Neuromuscular Blockade

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124437
Enrollment
Unknown
Registered
2026-05-12
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Sponsors

Cancer Hospital Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male and female patients aged between 18 and 80 years; 2. ASA <= Class III; 3. Body mass index (BMI) < 40 kg/m^2; 4. Elective esophageal cancer radical surgery expected to last at least 3 hours.

Exclusion criteria

Exclusion criteria: 1.Previous history of thoracic or abdominal surgery; 2.History of allergy to general anesthetics; 3.Severe cardiovascular or cerebrovascular dysfunction; 4.Suspected or diagnosed neuromuscular disease; 5.Anticipated requirement for prolonged mechanical ventilation postoperatively; 6.Liver cirrhosis (Child-Pugh class B or C); 7.Chronic renal failure requiring dialysis.

Design outcomes

Primary

MeasureTime frame
Incidence of Recurrent Neuromuscular Blockade (TOFR < 0.9 detected post-extubation);

Secondary

MeasureTime frame
The incidence of residual neuromuscular block in both groups (failure to achieve TOFR = 0.9 at 10 min after administration of sugammadex 4 mg/kg).;Changes in skeletal muscle area at the L3 level before and after chemotherapy;Skeletal muscle pathological changes in the two groups;Changes in mechanical properties of skeletal muscle cells in both groups;Difference in intraoperative rocuronium dosage between the two groups;

Countries

China

Contacts

Public ContactLi Huixian

Cancer Hospital Chinese Academy of Medical Sciences

lihuixian1227@aliyun.com+86 10 87787042

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026